Header

Breast: Metastatic Clinical Trials

Category:Adult
Status:Active

Displaying trials 1 - 30 of 47 in total

ZK219477 (Sagopilone) in Patients With Breast Cancer and Brain Metastases

The purpose of this research study is to determine the effects (good and bad) of ZK219477(sagopilone) on participants and their cancer. ZK219477 is a chemotherapy drug that is thought to work by in...

Diagnosis: Brain/Neuro Cancer: Other Non-Glioblastoma, Breast: Metastatic

Phase: 2

Protocol Number: 06-268

Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer

This phase II study will test cancer to see if it has a HER2 mutation and, if so, see how HER2 mutated cancer responds to treatment with neratinib.

Diagnosis: Breast: Metastatic

Phase: 2

Protocol Number: 13-237

Efficacy and Safety of GTx-024 in Patients With ER+/AR+ Breast Cancer

The purpose of this study is to determine if GTx-024 at different dosages (9 mg or 18 mg) is effective and safe in the treatment of patients with metastatic or locally advanced ER+ and AR+ breast c...

Diagnosis: Breast: Metastatic

Phase: 2

Protocol Number: 15-451

Avoiding Growth Factor During Paclitaxel Treatment in Breast Cancer

This research study is testing the safety and feasibility of delivering the 4 cycles of 'dose-dense' paclitaxel without the use of Neulasta (Pegfilgrastim) as a Granulocyte Colony-stimulati...

Diagnosis: Breast: Metastatic, Breast: Early Stage Disease

Phase: 2

Protocol Number: 15-516

A Study of Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Metastatic Breast Cancer

Approximately 70 patients with HR+ advanced breast cancer will be enrolled. All patients will receive either fulvestrant (500 mg IM every 2 weeks x 3 then every four weeks) or tamoxifen (20 mg PO d...

Diagnosis: Breast: Metastatic

Phase: 2

Protocol Number: 16-035

A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer

The main purpose of this study is to evaluate the safety and efficacy of abemaciclib in combination with pembrolizumab in participants with advanced non-small cell lung cancer (NSCLC) or hormone re...

Diagnosis: Lung Cancer, Breast: Metastatic

Phase: 2

Protocol Number: 16-216

Study of ONT-380 vs Placebo in Combo w/ Capecitabine & Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer

The purpose of this study is to assess the effect of ONT-380 vs. placebo in combination with capecitabine and trastuzumab on progression-free survival (PFS) per RECIST 1.1 based on independent cent...

Diagnosis: Breast: Metastatic

Phase: 2

Protocol Number: 16-092

A Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of VT-464 in Patients With Advanced Breast Cancer

The goal of this clinical study is to determine the safety, tolerability, pharmacokinetics and activity of VT-464, a lyase-selective inhibitor of CYP17, in patients with advanced breast cancer.

Diagnosis: Breast: Metastatic

Phase: 1 / 2

Protocol Number:

An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.

Participants that have breast cancer that has spread to other parts of the body, is positive for a protein called HER2, and has not responded to standard treatment. This research study is a way of ...

Diagnosis: Breast: Metastatic

Phase: 1 / 2

Protocol Number: 15-530

Palbociclib With Everolimus + Exemestane In BC

This research study is studying a combination of targeted therapy and hormonal therapy as a possible treatment for breast cancer that has spread to other places in the body and is hormone receptor ...

Diagnosis: Breast: Metastatic

Phase: 1 / 2

Protocol Number: 16-177

Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer

The purpose of this trial is to inform the future clinical development of the two investigational agents in ER+ breast cancer, LEE011 (CDK4/6 inhibitor) and BYL719 (PI3K-alpha inhibitor). This is a...

Diagnosis: Breast: Metastatic

Phase: 1

Protocol Number: 13-367

A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread

The main purpose of this study is to evaluate the safety of a study drug known as LY2835219 in combination with different therapies (letrozole, anastrozole, tamoxifen, exemestane, exemestane plus e...

Diagnosis: Breast: Metastatic

Phase: 1

Protocol Number: 14-070

A Safety Study of SGN-LIV1A in Breast Cancer Patients

This study will examine the safety and tolerability of SGN-LIV1A in patients with metastatic breast cancer. Increasing doses of SGN-LIV1A will be given every 3 weeks alone or in combination with tr...

Diagnosis: Breast: Metastatic

Phase: 1

Protocol Number: 14-306

Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers

To characterize the safety and tolerability, identify recommended doses and regimens for future studies, pharmacokinetics (PK), pharmacodynamics (PD) and anti-tumor activity of LSZ102 as a single a...

Diagnosis: Breast: Metastatic

Phase: 1

Protocol Number:

A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer

This is a multicenter, open label, Phase 1b study in patients with mBC. This study will have a dose escalation to identify the maximum tolerated dose (MTD) of the combination of gedatolisib plus pa...

Diagnosis: Breast: Metastatic

Phase: 1

Protocol Number:

Olaparib and Hsp90 Inhibitor AT13387 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer

This phase I trial studies the side effects and best dose of olaparib and Hsp90 inhibitor AT13387 when given together in treating patients with solid tumors that have spread to other places in the ...

Diagnosis: Breast: Metastatic, GYN: Ovarian, Fallopian, Peritoneal Cancer

Phase: 1

Protocol Number: 17-715

Novel Social Media Intervention For Older Br CA Patients

The number of patients 60 and older with breast cancer is increasing as our population ages. Despite the fact that the majority of breast cancers occur in patients 60 and over, these patients are c...

Diagnosis: Breast: Metastatic

Phase: N/A

Protocol Number: 15-326

Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy

This randomized phase III trial studies axillary lymph node dissection to see how well it works compared to axillary radiation therapy in treating patients with node-positive breast cancer treated ...

Diagnosis: Breast: Metastatic

Phase:

Protocol Number: 14-316

An Open Label, Phase II Trial of Continuous Low-Irradiance Photodynamic Therapy (CLIPT) Using Verteporfin (Visudyne®) for the Treatment of Cutaneous Metastases of Breast Cancer

The purpose of this Phase II study is to evaluate the efficacy and safety of Continuous Low- Irradiance Photodynamic Therapy (CLIPT) when used with Verteporfin in the treatment of cutaneous metasta...

Diagnosis: Breast: Metastatic

Phase:

Protocol Number: 16-370

Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2

This Phase 1b trial is an open label, multi-center study of XMT-1522 administered as an intravenous infusion once every three weeks. The dose escalation part of the study will establish the maximum...

Diagnosis: Breast: Metastatic, Solid Tumor/Phase I

Phase:

Protocol Number: 16-472

CISPLATIN + AZD-1775 In Breast Cancer

This research study is studying a combination of drugs as a possible treatment for triple-negative breast cancer that has spread to other areas of the body. The names of the study interventions inv...

Diagnosis: Breast: Metastatic

Phase:

Protocol Number: 16-264

A Study Of Pembrolizumab In Combination With Trastuzumab-DM1

This research study is studying a combination of drugs as a possible treatment for metastatic breast cancer. The interventions involved in this study are: - Pembrolizumab - Trastuzumab emtansine (a...

Diagnosis: Breast: Metastatic

Phase:

Protocol Number: 16-492

A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine

This is an open-label, randomized, active comparator, multicenter, international Phase 3 study of NKTR-102 versus TPC in patients with metastatic breast cancer who have stable brain metastases and ...

Diagnosis: Breast: Metastatic

Phase:

Protocol Number: 16-553

Phase II PEMBROLIZUMAB + PALLIATIVE RADIOTHERAPY IN BC

This research study is studying radiation therapy in combination with an immunotherapy as a possible treatment for metastatic hormone receptor (HR) positive, HER2-negative breast cancer. The interv...

Diagnosis: Breast: Metastatic

Phase:

Protocol Number: 16-588

Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors

This is an open-label, two-part, multiple study to evaluate the safety and tolerability of DS-8201a in patients with advanced solid malignant tumors.

Diagnosis: Breast: Metastatic

Phase:

Protocol Number: 16-520

Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer

The primary objective of this study is to demonstrate that the combination of palbociclib with anti-HER2 therapy plus endocrine therapy is superior to anti-HER2-based therapy plus endocrine therapy...

Diagnosis: Breast: Metastatic

Phase:

Protocol Number: 17-220

Palbociclib After CDK and Endocrine Therapy (PACE)

This research study is studying three combinations of drugs as treatments for breast cancer. The drugs involved in this study are: - Fulvestrant - Fulvestrant with Palbociclib - Fulvestrant with Pa...

Diagnosis: Breast: Metastatic

Phase:

Protocol Number: 17-101

Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer

This clinical trial is studying the drug Ribociclib (LEE011) in combination with an immunotherapy drug called PDR001 (a therapy that uses the body's own immune system to control cancer) as a po...

Diagnosis: GYN: Ovarian, Fallopian, Peritoneal Cancer, Breast: Metastatic

Phase:

Protocol Number: 17-285

Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer

This research study is studying a drug called Neratinib with and without Fulvestrant as possible treatments for HER2-positive breast cancer . The interventions involved in this study are: - Neratin...

Diagnosis: Breast: Metastatic

Phase:

Protocol Number: 17-318

A Phase 1, First-in-Human, Multi-Part Study of RAD140 in Postmenopausal Women With Hormone Receptor Positive Breast Cancer

The primary purpose of this study is to evaluate the clinical safety profile, tolerability, and pharmacokinetic (PK) characteristics of RAD140 in hormone receptor positive breast cancer.

Diagnosis: Breast: Metastatic

Phase:

Protocol Number: 17-186

1
<< Previous
'